Oppenheimer set a $85.00 price target on Neurocrine Biosciences (NASDAQ:NBIX) in a research report sent to investors on Tuesday. The brokerage currently has a buy rating on the stock.

A number of other analysts have also weighed in on NBIX. Deutsche Bank restated a buy rating and set a $79.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Citigroup reiterated a buy rating and issued a $79.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Robert W. Baird reiterated a buy rating and issued a $84.00 price target on shares of Neurocrine Biosciences in a research note on Friday, November 3rd. Piper Jaffray Companies set a $68.00 price target on shares of Neurocrine Biosciences and gave the company a buy rating in a research note on Thursday, August 24th. Finally, Needham & Company LLC reiterated a buy rating and issued a $58.00 price target on shares of Neurocrine Biosciences in a research note on Sunday, September 17th. One analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $78.88.

Shares of Neurocrine Biosciences (NASDAQ:NBIX) traded down $0.55 on Tuesday, hitting $70.42. 887,700 shares of the stock traded hands, compared to its average volume of 1,095,921. Neurocrine Biosciences has a 1-year low of $37.35 and a 1-year high of $75.98. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.36. The business had revenue of $60.77 million for the quarter, compared to analyst estimates of $29.38 million. During the same period in the prior year, the company posted ($0.43) EPS. analysts predict that Neurocrine Biosciences will post -1.74 EPS for the current year.

In other Neurocrine Biosciences news, insider Dimitri E. Grigoriadis sold 30,000 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $74.58, for a total value of $2,237,400.00. Following the completion of the sale, the insider now owns 77,691 shares in the company, valued at approximately $5,794,194.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Darin Lippoldt sold 6,279 shares of Neurocrine Biosciences stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $75.04, for a total value of $471,176.16. Following the completion of the sale, the insider now owns 19,436 shares of the company’s stock, valued at approximately $1,458,477.44. The disclosure for this sale can be found here. In the last quarter, insiders have sold 90,877 shares of company stock valued at $6,568,617. 4.80% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company lifted its position in Neurocrine Biosciences by 7.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after acquiring an additional 193 shares in the last quarter. Comerica Bank acquired a new position in shares of Neurocrine Biosciences in the 3rd quarter valued at approximately $210,000. Trexquant Investment LP acquired a new position in shares of Neurocrine Biosciences in the 3rd quarter valued at approximately $246,000. World Asset Management Inc acquired a new position in shares of Neurocrine Biosciences in the 3rd quarter valued at approximately $246,000. Finally, Stifel Financial Corp acquired a new position in shares of Neurocrine Biosciences in the 3rd quarter valued at approximately $246,000.

COPYRIGHT VIOLATION NOTICE: “Oppenheimer Analysts Give Neurocrine Biosciences (NBIX) a $85.00 Price Target” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/oppenheimer-analysts-give-neurocrine-biosciences-nbix-a-85-00-price-target/1766313.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with Analyst Ratings Network's FREE daily email newsletter.